The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially benefiting millions of Americans struggling with obesity.

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reported on Friday, citing documents from the Centers for Medicare and Medicaid Services.

People taking weight loss drugs typically start to lose weight within a few weeks. One study, funded by Mounjaro manufacturer Eli Lilly, found that Mounjaro led to 20 per cent weight loss after 72 weeks of treatment, whereas Wegovy led to 14 per cent weight reduction.